erenumab

Ligand id: 9250

Name: erenumab

References
1. A-Gonz├ílez N, Castrillo A. (2011)
Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.
Biochim. Biophys. Acta, 1812 (8): 982-94. [PMID:21193033]
2. Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, Palmer K, Picard H, Mikol DD, Lenz RA. (2018)
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.
Cephalalgia, 38 (6): 1026-1037. [PMID:29471679]
3. Edvinsson L. (2018)
The CGRP Pathway in Migraine as a Viable Target for Therapies.
Headache, 58 Suppl 1: 33-47. [PMID:29697153]
4. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. (2018)
CGRP as the target of new migraine therapies - successful translation from bench to clinic.
Nat Rev Neurol, 14 (6): 338-350. [PMID:29691490]
5. Hansen JM, Hauge AW, Olesen J, Ashina M. (2010)
Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura.
Cephalalgia, 30 (10): 1179-86. [PMID:20855363]
6. Paemeleire K, MaassenVanDenBrink A. (2018)
Calcitonin-gene-related peptide pathway mAbs and migraine prevention.
Curr. Opin. Neurol., 31 (3): 274-280. [PMID:29432219]
7. Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP, Immke DC, Wild KD, Xu C. (2016)
Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor.
J. Pharmacol. Exp. Ther., 356 (1): 223-31. [PMID:26559125]
8. Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J et al.. (2016)
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Neurol, 15 (4): 382-90. [PMID:26879279]